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Methods 
Devices 
Absorb BVS were available in Mainz starting from May 2012, in Frankfurt in March 
2013, in Fribourg in June 2012 and in Luzern in Juli 2013. The database includes all 
patients treated with BVS until January 2015. 
 
Quantitative coronary angiography  
Digital angiograms were analysed with the use of an automated edge-detection system 
(Xcelera, Philips, the Netherlands). Quantitative measurements included lesion length, 
MLD (minimum lumen diameter), RVD (reference vessel diameter) and TIMI 
(thrombolysis in myocardial infarction) flow before and after BVS implantation using 
standardized definitions. Repeatability and reproducibility data are reported 
elsewhere(1). The % stenosis before implantation and % residual stenosis after BVS 
implantation were calculated as  
100 ∗ (𝑅𝑅𝑅 −𝑀𝑀𝑅)
𝑅𝑅𝑅
 
 
 
The maximum “footprint”, i.e. the maximum % of the vascular circumference occupied 
by struts, was calculated as: 
100 ∗  𝑂𝑂𝑂𝑂𝑂 𝐵𝑅𝐵 𝑠𝑂𝑂𝑠𝑠𝑠𝑂
𝐵𝑅𝐵 𝑙𝑂𝑙𝑙𝑂ℎ ∗ (π 𝑀𝑀𝑅)  
That is, the outer BVS surface per mm divided by the lumen circumference at the level 
of the MLD.  
As such, the maximum footprint reflects the ratio of the outer surface of the BVS struts 
to the vascular circumference at the level of the MLD. In a OCT cross-section, this 
would be the ratio of the white to the blue line.   
  
Data on the outer BVS surface were kindly provided by Dr Rapoza of Abbott Vascular.  
The scaled residual stenosis was calculated as  
100 ∗ (𝑙𝑛𝑛𝑛𝑙𝑠𝑙 𝐵𝑅𝐵 𝑑𝑛𝑠𝑛𝑂𝑂𝑂𝑂 −  𝑀𝑀𝑅) (𝑙𝑛𝑛𝑛𝑙𝑠𝑙 𝐵𝑅𝐵 𝑑𝑛𝑠𝑛𝑂𝑂𝑂𝑂)  
and reflects the degree of deployment of the BVS as compared to the theoretical 
nominal value. Of note, in cases where the BVS is implanted or postdilated to a 
diameter larger than the nominal (MLD larger than nominal BVS diameter), this value 
becomes negative. The scaled residual stenosis reflects the expansion of the BVS 
rather than that of the vessel and therefore provides information that is slightly different 
from % residual stenosis: a negative scaled stenosis, for instance, reflects the 
expansion of the BVS above its nominal value, independently of the whether the RVD 
was reached or not. 
 “Undersizing” was defined as the implantation of a BVS with a nominal diameter 20% 
or more smaller than the RVD, and calculated as the ratio of  
𝑙𝑛𝑛𝑛𝑙𝑠𝑙 𝐵𝑅𝐵 𝑑𝑛𝑠𝑛𝑂𝑂𝑂𝑂
𝑅𝑅𝑅
< 0.8 
Correspondingly, oversizing was  
𝑙𝑛𝑛𝑛𝑙𝑠𝑙 𝐵𝑅𝐵 𝑑𝑛𝑠𝑛𝑂𝑂𝑂𝑂
𝑅𝑅𝑅
> 1.2 
 
Further definitions and reproducibility data are presented in a recent publication(1).  
 
Selection of the control group and matching 
For the selection of the control group, 2 patients with BVS implantation and no ScT 
were matched for each ScT patient. For matching, the clinical variables which showed 
a P<0.05 in the multivariable analysis were used. As well, patients were matched using 
the following criteria which clearly interfere with QCA measurements: BVS diameter 
and length, acute coronary syndrome and complete occlusion at the index procedure. 
Patients and controls were identical for these variables. Analyses were performed 
treating the two groups as independent samples. For the assessment of stent 
implantation, standardized definitions were used(2). While intracoronary imaging 
methods allow acquisition at a higher resolution and are in principle better suited for 
this analysis, definitions are as yet less standardized and these methods are less 
suited for large databases such as the present one. 
   
The impact of a BVS-specific implantation protocol 
Triggered by the initial observations of an unexpectedly high incidence of ScT(3), and 
based on preliminary findings of incomplete BVS expansion in cases of ScT(4) and 
improved acute results using 1:1 ballon:vessel predilation and postdilation(5), a major 
focus was put internationally on strenghtening BVS implantation recommendations. By 
review of the internal mortality and morbidity conferences, a precise timepoint (January 
2014) was identified, in which these recommendations were put into place in our 
Institutions. The outcome of patients treated during 2012 and 2013 (“early experience”) 
was compared to that of patients treated in 2014 (“BVS-specific protocol”). In order to 
limit the effect of confounders, this analysis was restricted to a subgroup of 4 expert 
operators who consistently applied the same implantation techniques.  
 Description of implantation procedures: 
During 2012 and 2013 (“early experience”), BVS were implanted using traditional 
“metal DES” methods, consisting of predilation using undersized semicompliant 
balloons and no systematic use of postdilation.  
Starting January 2014, the following set of recommendations, which was later 
partially included in the 2015 experts review(6), was implemented:  
1- Predilation using a noncompliant balloon of the same size as the RVD (several 
dilations were allowed until a 1:1 ratio angiographically was achieved). 
2- BVS implantation only in case of full expansion of the PTCA balloon as 
demonstrated by angiography in two orthogonal planes (i.e. absence of any 
indentation >10%). 
3- Implantation of a BVS with pressures of the same size as the RVD (1:1:1 ratio 
RVD:predilation ballon:BVS) at a pressure comprised between 10 and 12 ATM. 
4- Postdilation with NC Balloons of the same size or, when necessary based on 
reassessment of RVD, up to a maximum of 0.5mm larger at a pressure of 14-
16ATM. 
The implantation strategy did not mandate the use of imaging techniques, which was 
left to the operator´s discretion. Even though not systematically used, it needs to be 
acknowledged here that optical coherence tomography allows detecting stent 
underexpansion, malapposition, and, at later time points, the presence of evaginations, 
uncovered struts, and neoatherosclerosis as risk factors for stent thrombosis(7) and 
might therefore be of further help. Further, intracoronary imaging provides information 
on the nature of coronary lesion, the presence of calcifications and the need of 
postdilation(6). 
 
Statistical analysis 
Continuous variables are presented as mean±SD or median[interquartile range - 
IQR] and were compared using a Student’s unpaired t-test, Mann-Whitney, Kruskall-
Wallis or analysis of variance based on the inspection of the Q-Q plots. Categorical 
variables are presented as counts and percentages, and were compared using chi-
square or Fisher’s exact tests, as appropriate. Kaplan-Meier curves were built to derive 
the event rates and plot time-to-event curves. Cox proportional hazards analysis was 
performed to identify the clinical and procedural parameters relevant for the endpoint 
(the covariates screened in univariate models are listed in Tables 1, 2, 4, 5). A 
multivariable analysis of parameters selected at P<0.20 by univariate analysis was 
performed to identify the independent predictors of ScT and to estimate adjusted hazard 
ratios (HRs) and 95% confidence intervals (CIs). Similar uni- and multivariable analysis 
was repeated to address the hypothesis that the introduction of a BVS-specific 
implantation strategy would be associated with a reduction in the incidence of ScT. To 
address potential bias due to non-random assignment to implantation strategies, a 
propensity score model was built from a logistic regression model, using the 
implantation strategy as an outcome. Covariates were first screened at P<0.20, and the 
covariates meeting this criterion were jointly entered into a multivariable model, 
subjected to backward elimination, using the Akaike information criterion as a selection 
and stopping criterion. The resulting propensity score was subsequently used for 
adjustment in the Cox models.  
The impact of QCA parameters was assessed using a nested case-control design. Two 
control patients were matched for each ScT patient as described above. Apart from 
these criteria, the patients were randomly chosen from the overall database. Conditional 
logistic regression models were used for univariate screening with P<0.20, to obtain covariates 
for subsequent adjustment when evaluating QCA parameters in multivariable models. Since 
these parameters are mathematically correlated with each other, separate analyses 
were performed for MLD, RVD, and % scaled residual stenosis. To investigate potentially 
promising cutoffs, we dichotomized QCA parameters, and for each a grid of values of sensitivity 
and specificity were calculated using ROC analysis, using observation weights proportional to 
the number of potential controls available for each case to accommodate the nested case-
control design. The positive predicted value was calculated based on the prevalence of 3% 
observed in the general database. Statistical tests and analyses were performed with 
Medcalc (Mariakerke, Belgium), SPSS22 (IBM, USA), and using the R statistical 
environment (R version 3.1.3). 
 
Results 
 
QCA analysis 
Uni- and multivariable Cox regression analyses were conducted to assess the 
association of QCA parameters with ScT (Tables 2-10S). These analyses confirmed 
that MLD post-PCI, RVD, residual scaled stenosis, and maximum footprint are 
independently associated with the risk of ScT, the largest effect being associated with 
footprint. In contrast, the % residual stenosis was not significantly associated with ScT.  
 
 Implantation protocol analysis 
Prior to enactment of BVS-specific implantation recommendations (“early experience” 
group), 369 patients were treated with 542 BVS. This represented 20% of the patients 
undergoing PCI and 19% of the stents implanted during the same period. Following the 
implementation of the BVS-specific implantation protocol, 415 BVS were implanted in 
292 patients, i.e. 24%  of the patients undergoing PCI and 26% of the stents used (both 
P=0.01). 
A number of clinical or procedural characteristics showed relevant differences between 
the two periods (Tables 6 and 7S): the prevalence of hypertension, hyperlipidemia and 
diabetes, as well as the prevalence of lesions requiring overlapping scaffolds were 
higher in the patients treated in 2014. In contrast, the LVEF of patients treated in 2014 
was lower. Prasugrel was prescribed more frequently and ticagrelor less frequently in 
2014. Most importantly, postdilation was performed more systematically in 2014. In 
multivariable analysis, while none of the clinical and procedural characteristics (except 
for treatment of ostial lesions) was associated with differences in the incidence of ScT, 
the implementation of a BVS-specific implantation strategy was associated with ~ 70% 
reduced incidence of events, corresponding to a HR of 0.26[0.08-0.90] (Table 4). 
  
Table 1. Quantitative coronary analysis – descriptive statistics. All in-BVS analysis.  
 Pre-procedure After BVS implantation 
 BVS Thrombosis 
(n=42) 
Control 
(n=84) 
P between 
groups 
BVS Thrombosis 
(n=42) 
Control 
(n=84) 
P between 
groups 
       
Stenosis length, mm 15.8±7.3 13.4±0.1 0.111    
MLD, mm 0.66±0.59 0.68±0.51 0.849 2.39±0.58 2.85±0.49 0.000006 
RVD, mm 2.77±0.58 3.13±0.66 0.003 2.93±0.58 3.41±0.52 0.000015 
TIMI, n of pts (0,1,2,3) 15,2,19,48 7,6,11,18 0.057 0,0,20,64 0,0,2,40 0.016 
% Stenosis 76±20 77±16 0.660 19±12 16±7 0.157 
Maximum footprint, % - -  43±11 35±6 0.0000004 
Scaled residual stenosis - -  0.21±0.18 0.07±0.14 0.000002 
Undersizing, n(%)    2(5%) 18(21%) 0.019 
Oversizing, n(%)    10(24%) 3(4%) 0.0009 
 
  
 
  
 Table 2. Analysis of the predictors of ScT in the QCA population.  
Covariate P HR 95%Cl 
Male 0.644 0.81 0.33-1.99 
Age  years 0.237 1.02 0.99-1.06 
Diabetes 0.061 0.33 0.11-1.05 
Family History 0.732 0.84 0.3-2.34 
GPIIbIIIA 0.268 0.54 0.19-1.6 
Hyperlipidemia 0.793 1.11 0.51-2.39 
Hypertension 0.357 0.66 0.27-1.61 
Smoking 0.472 1.37 0.58-3.19 
Prior stroke TIA 0.726 0.67 0.07-6.41 
Prior CABG 0.488 2.00 0.28-14.2 
Prior PCI 0.189 1.78 0.75-4.21 
eGFR 0.83 1.00 0.99-1.01 
N of vessels treated  0.79 0.89 0.39-2.02 
Vessel treated 0.011 0.58 0.37-0.88 
Lesion type B2 or C 0.312 0.68 0.32-1.44 
Bifurcation 0.910 1.07 0.32-3.59 
Proximal 0.545 1.25 0.61-2.54 
Mid-coronary 0.454 0.75 0.37-1.59 
Distal 0.850 0.90 0.29-2.75 
ACS 0.868 0.92 0.35-2.45 
Overlap 0.054 3.93 0.98-15.77 
Prasugrel 0.04 0.39 0.16-0.96 
Ticagrelor 0.147 1.89 0.8-4.48 
MLD 0.826 0.92 0.41-2.02 
RVD 0.001 0.22 0.08-0.55 
% Stenosis before PCI 0.618 0.99 0.97-1.02 
MLD after PCI 0.000 0.09 0.03-0.28 
RVD after PCI 0.000 0.1 0.03-0.31 
Residual stenosis 0.182 1.03 0.991.07 
Scaled residual stenosis 0.000 462.92 20.15-10634.73 
Maximum footprint 0.000 1.16 1.08-1.25 
 
Table 3. Multivariable analysis including MLD before PCI. 
Covariate P HR 95% Cl 
Diabetes 0.094 0.33 0.09-1.21 
Prior PCI 0.190 1.96 0.72-5.36 
Overlap 0.084 4.00 0.83-19.20 
Vessel treated 0.062 0.64 0.41-1.02 
Prasugrel 0.06 0.33 0.11-1.05 
Ticagrelor 0.919 0.95 0.33-2.74 
MLD 0.784 0.88 0.35-2.22 
 
 
Table 4. Multivariable analysis including RVD before PCI 
Covariate P HR 95% Cl 
Diabetes 0.215 0.43 0.12-1.63 
Prior PCI 0.198 1.94 0.71-5.35 
Overlap 0.064 4.86 0.91-25.81 
Vessel treated 0.167 0.70 0.42-1.16 
Prasugrel 0.208 0.48 0.15-1.51 
Ticagrelor 0.797 1.16 0.37-3.67 
RVD 0.014 0.27 0.1-0.77 
 
 
Table 5. Multivariable analysis including the % stenosis before PCI 
Covariate P HR 95% Cl 
Diabetes 0.086 0.32 0.09-1.18 
Prior PCI 0.229 1.85 0.68-5.05 
Overlap 0.078 4.19 0.85-20.64 
Vessel treated 0.061 0.64 0.41-1.02 
Prasugrel 0.061 0.33 0.11-1.05 
Ticagrelor 0.883 0.92 0.32-2.66 
% Stenosis 0.815 1.00 0.97-1.03 
 
 
Table 6. Multivariable analysis including the MLD after PCI 
Covariate P HR 95% Cl 
Diabetes 0.157 0.35 0.08-1.51 
Prior PCI 0.162 2.40 0.70-8.19 
Overlap 0.106 4.31 0.74-25.32 
Vessel treated 0.247 0.72 0.41-1.26 
Prasugrel 0.354 0.55 0.15-1.97 
Ticagrelor 0.33 2.06 0.49-8.65 
POST MLD 0.001 0.05 0.01-0.28 
 
Table 7. Multivariable analysis including the RVD after PCI 
Covariate P HR 95% Cl 
Diabetes 0.184 0.41 0.11-1.53 
Prior PCI 0.453 1.51 0.52-4.42 
Overlap 0.183 3.19 0.58-17.64 
Vessel treated 0.459 0.82 0.48-1.39 
Prasugrel 0.315 0.53 0.15-1.83 
Ticagrelor 0.542 1.48 0.42-5.26 
POST RVD 0.002 0.13 0.04-0.46 
 
Table 8. Multivariable analysis including the residual stenosis after PCI 
Covariate P HR 95% Cl 
Diabetes 0.106 0.34 0.09-1.26 
Prior PCI 0.131 2.20 0.79-6.14 
Overlap 0.078 4.13 0.85-20.02 
Vessel treated 0.038 0.60 0.37-0.97 
Prasugrel 0.066 0.33 0.10-1.08 
Ticagrelor 0.956 0.97 0.32-2.92 
Residual stenosis 0.071 1.05 0.1-1.10 
 
Table 9. Multivariable analysis including the scaled residual stenosis after PCI 
Covariate P HR 95% Cl 
Diabetes 0.192 0.39 0.09-1.61 
Prior PCI 0.146 2.36 0.74-7.49 
Overlap 0.072 5.40 0.86-33.93 
Vessel treated 0.179 0.69 0.4-1.19 
Prasugrel 0.255 0.48 0.14-1.69 
Ticagrelor 0.401 1.81 0.45-7.23 
Scaled residual 
stenosis 
0.001 1714.38 20.07-146454.09 
 
Talble 10. Multivariable analysis including the maximum footprint 
Covariate P HR 95% Cl 
Diabetes 0.136 0.30 0.06-1.47 
Prior PCI 0.152 2.43 0.72-8.2 
Overlap 0.149 3.81 0.62-23.47 
Vessel treated 0.176 0.68 0.39-1.19 
Prasugrel 0.371 0.54 0.14-2.06 
Ticagrelor 0.393 1.85 0.45-7.65 
Maximum footprint 0.001 1.20 1.08-1.33 
 Table 11. Implantation protocol analysis – patient and lesion characteristics divided by 
the presence or absence of ScT during follow-up. 
 
 All patients Patients without 
thrombosis (n=640) 
In BVS Thrombosis 
(n=21) 
P 
Patient-level analysis 
Male sex 526/661(80%) 506/640(79%) 17/21(81%) 0.939 
Age, years 62(54-73) 62(54 – 73) 61(54.5 - 69.3) 0.464 
Hypertension 478/661(72%) 461/640(72%) 17/21(81%) 0.662 
Hyperlipidemia 268/660(41%) 260/639(41%) 8/21(38%) 0.954 
Diabetes 140/661(21%) 137/640(21%) 3/21(14%) 0.72 
Smoking 272/658(41%) 263/637(41%) 9/21(43%) 0.993 
Previous PCI 186/659(28%) 181/638(28%) 5/21(24%) 0.886 
Previous CABG 14/661(2%) 14/640(2%) 0/21(0%) 0.777 
History of stroke 27/661(4%) 27/640(4%) 0/21(0%) 0.618 
ACS 
STEMI 
 
392/661(59%) 
164/661(25%) 
379/640(59%) 
160/640(25%) 
13/21(62%) 
4/21(19%) 
0.956 
0.715 
eGFR, ml/min 
 
82±23 82±22 92±33 0.064 
LVEF, % 52±8 52±8 52±8 0.994 
Number of vessels 
treated 
1.1±0.4 1.1±0.4 1.2±0.4 0.397 
Number of BVS 
implanted  
1.4±0.9 1.4±0.9 1.6±0.9 0.5000 
Mean BVS diameter, 
mm 
3.0±0.4 3.0±0.4 3.0±0.3 0.733 
Minimum BVS 
diameter, mm 
3.0±0.4 3.0±0.4 3.0±0.4 0.775 
Total BVS length, 
mm 
18(18-30) 18(18-30) 28(18- 46) 0.255 
  
 
  
Overlap 86/650(13%) 82/630 4/20 0.567 
Total BVS surface, 
cm2 
1.97(1.81-3.08) 1.97(1.81-3.08) 2.76(1.81 - 4.69) 0.066 
Total outer BVS 
surface, cm2 
0.58(0.52-0.91) 0.58(0.52-0.91) 0.79(0.52 - 1.36) 0.067 
IIbIIIa inhibitors 176/660(27%) 172/640 4/20 0.666 
DAPT Type  
Clopidogrel 
Prasugrel 
Ticagrelor 
 
200/661(30%) 
331/661(50%) 
128/661(19%) 
 
197/640 
319/640 
122/640 
 
3/21 
12/21 
6/21 
0.548 
0.168 
0.663 
0.421 
Predilation 656/661(99%) 636/640 20/21 0.2869 
Postdilation 365/656(56%) 354/636 11/20 0.865 
Lesion-level analysis N=764 N=21 
Lesion type 
B2 or C 
327/785(42%) 315/764 12/21 0.217 
Bifurcation lesion 96/673(14%) 94/655 2/18 0.926 
Ostial lesion 60/785(8%) 55/764 5/21 0.016 
Table 12. Implantation protocol – patient and lesion characteristics divided by treatment 
group. 
 
 Early experience group 
(n=369) 
BVS implantation 
protocol (n=292) 
P 
Patient-level analysis 
Male sex 293/369(80%) 230/292(79%) 0.788 
Age, years 62(54–73) 62(54-72) 0.775 
Hypertension 252/369(68%) 226/291(78%) 0.008 
Hyperlipidemia 135/369(37%) 133/290(46%) 0.020 
Diabetes 68/369(18%) 72/291(25%) 0.061 
Smoking 161/369(44%) 111/290(38%) 0.182 
Previous PCI 101/368(27%) 85/291(29%) 0.168 
Previous CABG 11/368(3%) 3/291(1%) 0.146 
History of stroke 16/367(4%) 11/291(4%) 0.86 
ACS 
STEMI 
 
215/369(58%) 
100/369(27%) 
177/292(61%) 
64/292(22%) 
0.572 
0.150 
 
eGFR, ml/min 
 
84±24 81±22 0.116 
LVEF, % 54±8 51±9 0.001 
Number of 
vessels treated 
 
1.1±0.4 1.1±0.4 0.182 
Number of BVS 
implanted  
1.5±0.9 1.4±0.9 0.493 
Mean BVS 
diameter, mm 
3.0±0.4 3.0±0.4 0.172 
Minimum BVS 
diameter, mm 
2.90.4 3.0±0.4 0.193 
Total BVS 
length, mm 
27.8±18.5 27.7±19.3 0.944 
Overlap 35/365(10%) 51/285(18%) 0.003 
Total BVS 
surface, cm2 
1.97(1.81 – 3.08) 1.81(1.35 – 2.76) 0.637 
Total outer BVS 
surface, cm2 
0.58(0.52 – 0.91) 0.58(0.40 – 0.79) 0.647 
IIbIIIa inhibitors 99/368(27%) 77/291(26%) 0.485 
Clopidogrel 
Prasugrel 
Ticagrelor 
112/369(30%) 
169/369(46%) 
87/369(24%) 
88/292(30%) 
162/292(55%) 
41/292(14%) 
0.511 
0.017 
0.003 
Predilation 367/368(100%) 289/292(99%) 0.330ǂ 
Postdilation 111/364(30%) 254/292(87%) 4*10-51 
Lesion-level analysis                   
Lesion type 
B2 or C 
193/430(45%) 137/355(39%) 0.089 
Bifurcation 
lesion 
74/343(21%) 22/330(7%) 0.001 
Ostial lesion 31/430(7%) 29/354(8%) 0.712 
ǂFisher´s test 
 
 
 
 
  
 
Figures  
 
 
Figure 1. Incidence of ScT in the four centers. No difference was observed.  
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